TRDA Q2 2023 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M

Gross Profit

-$8M-44.7% margin

Operating Income

-$16M-89.7% margin

Net Income

-$26M-142.7% margin

EPS (Diluted)

$-0.78

QoQ Revenue Growth

-28.1%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$37M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$494M

Total Liabilities

$287M

Stockholders' Equity

$207M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$0	—
Gross Profit	-$8M	$0	—
Operating Income	-$16M	-$24M	+30.9%
Net Income	-$26M	-$23M	-11.9%

Revenue Segments

Upfront Payment Revenue

$15M100%